Helixgate

Helixgate

Biotech Industry Intelligence

Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win

Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win

Published

on

Pfizer said a combination of two of its prostate cancer drugs — Talzenna and Xtandi — succeeded in a Phase 3 study and that it plans to ask regulators for earlier use of Talzenna, a PARP inhibitor …​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Biotech Industry Intelligence

Wave crashes on obesity disappointment

Wave crashes on obesity disappointment

Published

on

There’s a reason lots of companies are working on GLP-1-based drugs for obesity: The other stuff tends not to work. The latest biotech to learn this the hard way is Wave Life Sciences, which​ ​Read More

Continue Reading

Biotech Industry Intelligence

Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data

Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data

Published

on

Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data in Maze Therapeutics’ trial, according to Mizuho.​ ​Read More

Continue Reading

Biotech Industry Intelligence

Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure

Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure

Published

on

Boehringer Ingelheim said it plans to keep up high levels of R&D spending, and could look at China-based companies for dealmaking, as key planks of its strategic approach this year, board chairman Shashank Deshpande said …​ ​Read More

Continue Reading
Advertisement

Trending